- +971 50 312 9316
- info@menovivreclinic.com
- Mon-Fri: 8AM - 7PM | Sun: 8AM - 4PM
The hormones most commonly used in BHRT include:
Perimenopause and menopause represent the most common indication. Declining oestrogen, progesterone, and testosterone during this transition can produce a cascade of symptoms including hot flashes, night sweats, sleep disruption, mood instability, cognitive changes, reduced libido, vaginal dryness, and joint discomfort. BHRT addresses these at their hormonal root rather than managing each symptom in isolation. In post-menopause, the focus shifts toward prevention: supporting bone density, contributing to cardiovascular protection, and offering potential neuroprotective benefits when initiated within the appropriate clinical window.
Low testosterone is a frequently overlooked driver of persistent fatigue, reduced libido, brain fog, and low mood. BHRT can restore testosterone to physiological levels without the androgenic side effects associated with over-dosing. Where DHEA levels have declined due to chronic stress, ageing, or adrenal changes, targeted DHEA support within a protocol can improve energy, mood, and metabolic function. BHRT can also address hormonal imbalances arising from other endocrine changes across the life cycle, assessed individually by your Menovivre clinician.
Transdermal delivery is generally preferred at Menovivre because it bypasses hepatic first-pass metabolism, reducing the risk of blood clots compared to oral oestrogen tablets. This is consistent with guidance from the British Menopause Society and NICE.
Bioidentical hormones are structurally identical to those your body produces, which does confer advantages over some synthetic alternatives. However, any hormone therapy requires careful clinical assessment, individualised dosing, and ongoing monitoring. Safety is not inherent in the word bioidentical. It is achieved through proper evaluation and follow-up, particularly for patients with complex medical histories.
BHRT is most commonly associated with perimenopause and menopause, but hormonal imbalances occur across the life cycle. BHRT can support low testosterone, adrenal hormone changes, DHEA insufficiency, and other endocrine shifts at various stages of life.
A family history of breast cancer is not an automatic contraindication to BHRT. In many cases, therapy can be used safely with appropriate clinical oversight and hormone metabolism testing to ensure that potentially harmful oestrogen metabolites are not being produced. This is a deeply individual assessment, not a blanket exclusion.
A history of migraines is not a contraindication to BHRT. In fact, hormonal fluctuations are a common migraine trigger, and stabilising oestrogen levels through BHRT can reduce migraine frequency in some patients. The delivery method matters: transdermal oestrogen is generally preferred over oral forms for patients with migraine history.
Compounded and commercially manufactured bioidentical formulations differ in their regulatory oversight, quality assurance, and consistency of dosing. At Menovivre, we use pharmaceutical-grade formulations with full traceability, not unregulated compounded preparations sourced without clinical governance.
A: BHRT is a form of HRT. The distinction is that BHRT uses hormones that are molecularly identical to those produced by the human body, whereas conventional HRT may include synthetic progestins or conjugated oestrogens with a different molecular structure. At Menovivre, we use body-identical hormones across our full HRT programme as well as our dedicated BHRT protocols.
A: Yes. BHRT can be legally prescribed by qualified physicians in the UAE. At Menovivre, all BHRT is prescribed under a formal clinical pathway, with comprehensive testing and ongoing monitoring, in full compliance with Dubai Health Authority (DHA) standards.
A: This is determined through comprehensive blood testing, not through symptoms alone. Your oestradiol, progesterone, testosterone, DHEA, cortisol, and thyroid levels are all assessed as part of your baseline evaluation. In some cases, hormone metabolism testing is also conducted to understand how your body processes specific hormones before any prescription is written.
A: Yes. Pellet therapy is one of the delivery formats available at Menovivre for appropriate patients. Pellets offer sustained, steady-state hormone delivery over three to six months without daily administration. Suitability is assessed individually based on your clinical picture and personal preference.
A: In many cases, yes. Hormonal fluctuations are a common migraine trigger, and stabilising oestrogen through BHRT may actually reduce migraine frequency in some patients. Transdermal delivery is generally preferred over oral forms for patients with migraine history. This is assessed individually at consultation.
A: Yes. BHRT integrates naturally with several other Menovivre services. It is commonly combined with functional nutrition support, functional medicine protocols, and in some cases peptide therapy where there is a complementary clinical indication.
A: This is individual and depends on your clinical indication, symptom response, and long-term health goals. The British Menopause Society and NICE both support continuation of HRT for as long as the benefits outweigh the risks, which for many patients extends well beyond the traditional “lowest dose for shortest time” guidance. Your Menovivre clinician will review this with you at every follow-up.
